Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Assets (2018 - 2025)

Arcturus Therapeutics Holdings' Current Assets history spans 8 years, with the latest figure at $241.4 million for Q4 2025.

  • For Q4 2025, Current Assets fell 21.09% year-over-year to $241.4 million; the TTM value through Dec 2025 reached $241.4 million, down 21.09%, while the annual FY2025 figure was $241.4 million, 21.09% down from the prior year.
  • Current Assets reached $241.4 million in Q4 2025 per ARCT's latest filing, down from $249.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $470.0 million in Q1 2021 to a low of $241.4 million in Q4 2025.
  • Average Current Assets over 5 years is $348.5 million, with a median of $361.4 million recorded in 2024.
  • Peak YoY movement for Current Assets: skyrocketed 637.14% in 2021, then crashed 41.4% in 2022.
  • A 5-year view of Current Assets shows it stood at $379.0 million in 2021, then increased by 6.43% to $403.3 million in 2022, then fell by 4.15% to $386.6 million in 2023, then fell by 20.85% to $306.0 million in 2024, then decreased by 21.09% to $241.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Current Assets are $241.4 million (Q4 2025), $249.2 million (Q3 2025), and $274.5 million (Q2 2025).